Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecka Arnsrud Godtman

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|December 12, 2024
Four Years of Screening for Prostate Cancer with PSA and MRI. ReplyJonas Hugosson, Rebecka Arnsrud Godtman, Johan Stranne
European Urology|May 24, 2016
Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8Rebecka Arnsrud Godtman, Johan Stranne, Jonas Hugosson
European Urology|September 25, 2025
Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380Emmeli Palmstedt, Jonas Hugosson, Rebecka Arnsrud Godtman
European Urology|May 1, 2026
The PROSA trial: Some Prosaic CommentsRebecka Arnsrud Godtman, Jonas Wallström, Ola Bratt
European Urology|June 26, 2025
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 TrialEmmeli Palmstedt, Marianne Månsson, Jonas Hugosson, et al.
European Urology|January 6, 2015
Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trialRebecka Arnsrud Godtman, Erik Holmberg, Hans Lilja, et al.
The Journal of Urology|December 19, 2015
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate CancerRebecka Arnsrud Godtman, Sigrid Carlsson, Erik Holmberg, et al.
Lakartidningen|April 22, 2024
[Prostate cancer - diagnostics and screening]Rebecka Arnsrud Godtman, Ola Bratt, Tobias Nordström, et al.
European Urology|September 18, 2012
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trialRebecka Arnsrud Godtman, Erik Holmberg, Ali Khatami, et al.
Scandinavian Journal of Urology|October 25, 2021
Constitutive expression of inducible nitric oxide synthase in healthy rat urothelium?Rebecka Arnsrud Godtman, Lena Hallsberg, Zarah Löf-Öhlin, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|December 12, 2024
Four Years of Screening for Prostate Cancer with PSA and MRI. ReplyJonas Hugosson, Rebecka Arnsrud Godtman, Johan Stranne
European Urology|May 24, 2016
Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8Rebecka Arnsrud Godtman, Johan Stranne, Jonas Hugosson
European Urology|September 25, 2025
Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380Emmeli Palmstedt, Jonas Hugosson, Rebecka Arnsrud Godtman
European Urology|May 1, 2026
The PROSA trial: Some Prosaic CommentsRebecka Arnsrud Godtman, Jonas Wallström, Ola Bratt
European Urology|June 26, 2025
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 TrialEmmeli Palmstedt, Marianne Månsson, Jonas Hugosson, et al.
European Urology|January 6, 2015
Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trialRebecka Arnsrud Godtman, Erik Holmberg, Hans Lilja, et al.
The Journal of Urology|December 19, 2015
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate CancerRebecka Arnsrud Godtman, Sigrid Carlsson, Erik Holmberg, et al.
Lakartidningen|April 22, 2024
[Prostate cancer - diagnostics and screening]Rebecka Arnsrud Godtman, Ola Bratt, Tobias Nordström, et al.
European Urology|September 18, 2012
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trialRebecka Arnsrud Godtman, Erik Holmberg, Ali Khatami, et al.
Scandinavian Journal of Urology|October 25, 2021
Constitutive expression of inducible nitric oxide synthase in healthy rat urothelium?Rebecka Arnsrud Godtman, Lena Hallsberg, Zarah Löf-Öhlin, et al.
Pageof 6